 BOSTON, Oct. 07, 2021 GLOBE NEWSWIRE -- Ikena Oncology, Inc. Nasdaq: IKNA, Ikena, a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021. Both presentations highlight the potential of inhibitors of the transcription factor TEAD, a key mediator of Hippo pathway signaling, in cancer treatment. 